TAILIEUCHUNG - Chapter 086. Breast Cancer (Part 4)

If a nonpalpable mammographic lesion has a low index of suspicion, mammographic follow-up in 3–6 months is reasonable. Workup of indeterminate and suspicious lesions has been rendered more complex by the advent of stereotactic biopsies. Morrow and colleagues have suggested that these procedures are indicated for lesions that require biopsy but are likely to be benign—that is, for cases in which the procedure probably will eliminate additional surgery. When a lesion is more probably malignant, open biopsy should be performed with a needle localization technique. Others have proposed more widespread use of stereotactic core biopsies for nonpalpable lesions on. | Chapter 086. Breast Cancer Part 4 If a nonpalpable mammographic lesion has a low index of suspicion mammographic follow-up in 3-6 months is reasonable. Workup of indeterminate and suspicious lesions has been rendered more complex by the advent of stereotactic biopsies. Morrow and colleagues have suggested that these procedures are indicated for lesions that require biopsy but are likely to be benign that is for cases in which the procedure probably will eliminate additional surgery. When a lesion is more probably malignant open biopsy should be performed with a needle localization technique. Others have proposed more widespread use of stereotactic core biopsies for nonpalpable lesions on economic grounds and because diagnosis leads to earlier treatment planning. However stereotactic diagnosis of a malignant lesion does not eliminate the need for definitive surgical procedures particularly if breast conservation is attempted. For example after a breast biopsy with needle localization . local excision of a stereotactically diagnosed malignancy reexcision may still be necessary to achieve negative margins. To some extent these issues are decided on the basis of referral pattern and the availability of the resources for stereotactic core biopsies. A reasonable approach is shown in Fig. 86-4. Figure 86-4 Approaches to abnormalities detected by mammogram. f u follow-up. Breast Masses in the Pregnant or Lactating Woman During pregnancy the breast grows under the influence of estrogen progesterone prolactin and human placental lactogen. Lactation is suppressed by progesterone which blocks the effects of prolactin. After delivery lactation is promoted by the fall in progesterone levels which leaves the effects of prolactin unopposed. The development of a dominant mass during pregnancy or lactation should never be attributed to hormonal changes. A dominant mass must be treated with the same concern in a pregnant woman as any other. Breast cancer develops in 1 in every .

• Y học thường thức
• Breast Cancer
• bệnh học và điều trị
• bài giảng bệnh học
• tài liệu y khoa
• Harrisons Internal Medicine
• BMC Cancer
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Breast cancer management
• Gross anatomy
• The breast
• Breast cancer epidemiology
• Hereditary breast cancer genetics
• Prediction techniques
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Breast specific gamma imaging
• Diagnosing breast cancer during
• Ductal carcinoma in situ
• DNA methylation
• Breast epithelial cells
• Breast cancer campaign tissue bank
• Breast milk
• Axillary lymph node dissection
• Breast cancer related lymphedema
• Breast lymphatics level
• Ovarian cancer
• Mauritanian breast cancer patients
• Triple negative breast cancer
• Molecular subtype
• Cholesterol observed
• Female breast cancer
• Breast feeding
• World Health Organization
• Inflammatory breast cancer
• Case comparison study
• Family history of breast cancer
• Breast cancer risk factors
• Multiplex IBC families
• Carcinoma associated fibroblasts
• Breast cancer pathogenesis
• Breast cancer cell biology
• Cytokine molecules mediating
• Stage IV breast cancer
• Metastatic breast cancer
• Diagnostic marker
• Searching reliable
• Protein cancer biomarkers
• Breast fluid secretome
• breast cancer second edition
• Breast Sonography
• Radionuclide Imaging of the Breast
• Mammography
• Breast Reconstruction
• Chemotherapy for Breast Cancer
• Breast imaging
• Breast pathology
• Breast soft tissue
• Breast cancers
• Breast tumorigenesis
• Non steroidal anti inflammatory drug
• Hormone receptor positive breast cancer
• HER2 positive breast cancer
• Aggressive tumor phenotype
• Health care
• Including increased frequency
• Polygenic risk score
• Single nucleotide polymorphisms
• Artifcial neural network
• Estrogen receptor negative breast cancer
• Mammographic breast density
• Breast cancer risk
• Atypical hyperplasia
• Established risk factors
• Non melanoma skin cancer
• Metastatic cancer
• Reduce ethnic
• Multivariate models adjusting
• Cancer survivorship
• Cancer prevalence
• Statistical projection
• Toll like receptor 4
• +3725G C polymorphism
• Egyptian breast cancer atients
• Breast cancer cases than controls
• Post treatment breast cancer patients
• Pre treatment breast cancer
• Extraaxilary nodes
• Distance metastases
• Breast cancer cell lines
• Breast tumor subtypes
• Topoisomerase I
• Camptothecin sensivity
• Epithelial type
• Triplenegative breast carcinomas
• N terminal p63 isoforms